+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are studying the impact of the Accu-Chek SmartGuide continuous glucose monitoring CGM device in adults with Type 1 or insulin-dependent Type 2 diabetes who use multiple daily insulin injections. The trial compares the time their blood glucose levels stay within the target range of 70 to 180 mgdL when using the CGM device versus traditional self-monitoring of blood glucose SMBG. This open-label, randomized study aims to gather data on glucose management improvements with the new device. Participants are assigned to one of two groups one group uses the Accu-Chek SmartGuide CGM solution, which includes a sensor, a device, and smartphone apps that provide real-time glucose readings and data analysis. The control group continues using SMBG with a blinded CGM sensor during assessment periods, meaning they cannot see real-time glucose data. The study includes baseline and multiple assessment periods over 26 weeks to measure changes in glucose control markers. During the study, participants will have their blood glucose levels monitored and compared across different periods using the CGM or SMBG methods. Researchers will collect data on time spent within glucose target ranges, hypoglycemia and hyperglycemia events, average glucose levels, insulin doses, carbohydrate intake, and questionnaire scores related to diabetes distress and fear of hypoglycemia. The study lasts approximately 27 weeks, including baseline and three assessment periods, with multiple visits and data collection to understand the devices impact on glucose management.

Age: 18Years +All GendersPhase Not Applicable
20 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are investigating how noise in operating rooms affects patients under general anesthesia, focusing on its impact on bispectral index BIS values and hemodynamic stability. This observational study will enroll 70 adult patients aged 18 to 70 years with ASA physical status I-II who are scheduled for elective surgery. It aims to understand whether environmental noise influences anesthesia depth and patient safety during surgery. Participants will be divided into two groups based on the average noise level during surgery a noisy group with noise above 65 dB and a quiet group below 55 dB. Noise will be measured every 10 minutes using a calibrated sound level meter placed near the patients head without affecting care. BIS values will be recorded every 10 minutes, while blood pressure and heart rate will be monitored every 5 minutes. The study is strictly observational and does not change anesthesia or surgical procedures. During the study, participants will undergo standard clinical monitoring while noise and physiological data are collected throughout surgery. Researchers will analyze correlations between noise levels and BIS values, as well as the relationship between noise types, surgical specialties, and hemodynamic stability. This study involves no additional risks and will provide insights into how operating room noise may affect anesthesia management and patient safety.

Age: 18Years - 70YearsAll Genders
1 location
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of Imeroprubart in adults with active Chronic Inflammatory Demyelinating Polyneuropathy CIDP, a neurological disorder. This Phase 2b, multi-center, randomized, double-blind, placebo-controlled study focuses on adult participants who meet specific diagnostic criteria for CIDP or its variants. The study is sponsored by Immunovant Sciences GmbH and aims to understand how well Imeroprubart helps prevent relapses and improves disability and muscle strength in this population. Participants will receive either Imeroprubart or a matching placebo by subcutaneous injection once weekly. The initial treatment period lasts 24 weeks, with a further extension period of 52 weeks for continued evaluation. Imeroprubart is given as a dose 1 injection under the skin weekly during these periods, while the placebo group receives matching injections during the first 24 weeks. Throughout the study, participants will be regularly assessed for relapse status, disability scales, grip strength, muscle strength scores, and functional impairment from baseline up to Week 24. These assessments include standardized clinical scales such as the Inflammatory Rasch-Built Overall Disability Scale I-RODS and Medical Research Council Sum Score MRC-SS. Safety and efficacy are closely monitored, with the primary outcome focusing on the proportion of participants remaining relapse-free by Week 24. The total study duration extends until May 2030.

Age: 18Years +All GendersPhase 2
142 locations